MindBio Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Net Income	-3.97	-2.81	-0.41	-4.29	-7.47
Asset Writedown & Restructuring Costs	0.59	0.59	-	-	-
Loss (Gain) From Sale of Investments	-	-	0.01	0.02	-
Stock-Based Compensation	2	0.84	-	1.4	-
Other Operating Activities	0.39	0.29	0.19	0.95	1.93
Change in Accounts Payable	0.52	0.6	-0.06	-0.4	0.87
Change in Unearned Revenue	-	-	-0.12	0.12	-
Change in Other Net Operating Assets	0	0	-0	-0.01	-0.04
Operating Cash Flow	-0.46	-0.49	-0.38	-2.21	-4.72
Cash Acquisitions	0.01	0.01	-	-	-
Investment in Securities	-	-	-	-	-0.03
Investing Cash Flow	0.01	0.01	-	-	-0.03
Long-Term Debt Issued	-	-	-	-	6.38
Long-Term Debt Repaid	-	-0.01	-0.01	-0.11	-
Net Debt Issued (Repaid)	-0	-0.01	-0.01	-0.11	6.38
Issuance of Common Stock	0.44	0.44	-	1.15	-
Common Dividends Paid	-	-	-	-	-0.79
Other Financing Activities	-0	-0	0.28	-	-
Financing Cash Flow	0.44	0.43	0.27	1.04	5.59
Foreign Exchange Rate Adjustments	-0.02	-0.02	-0.07	0.18	-
Net Cash Flow	-0.03	-0.07	-0.18	-1	0.83
Levered Free Cash Flow	-0.56	-0.71	-0.79	-1.39	-
Unlevered Free Cash Flow	-0.25	-0.34	-0.57	-1.11	-
Change in Working Capital	0.53	0.6	-0.17	-0.29	0.82

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.